The Great Britain is witnessing a significant surge in interest surrounding entheogenic substances. Beyond the common use of psilocybin and LSD, scientists and adventurers are increasingly exploring less-charted territories, particularly copyright and the relatively new cannabinoid, CBG compound. This burgeoning community encompasses clinical trial